Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy

Introduction: Psoriasis significantly impacts a patient’s quality of life (QoL). Bimekizumab targets IL-17A and IL-17F, offering a broader blockade of the IL-17 pathway compared to other IL-17 inhibitors. Objectives: This study evaluated the clinical efficacy of bimekizumab in bio-naive and bio-e...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Annunziata Dattola, Nicoletta Bernardini, Elena Campione, Emanuele Amore, Simone Amato, Giacomo Caldarola, Clara De Simone, Domenico Giordano, Gaia Moretta, Vincenzo Panasiti, Gianluca Pagnanelli, Vincenzo Roberti, Ruslana Gaeta Shumak, Nevena Skroza, Ersilia Tolino, Paola Tribuzi, Salvatore Zanframundo, Luca Bianchi, Severino Persechino, Concetta Potenza, Giovanni Pellacani, Ketty Peris, Antonio Giovanni Richetta
Format:	Artigo
Sprog:	Inglês
Udgivet:	Mattioli1885 2025-04-01
Serier:	Dermatology Practical & Conceptual
Fag:	Bimekizumab, IL-17 Inhibition, Psoriatic Arthritis, IL-17, sensitives area, difficult to treat areas, psoriasis
Online adgang:	https://dpcj.org/index.php/dpc/article/view/4976
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!